C. Calbrix

Circulating PIK3CA mutation detection at diagnosis in non-metastatic inflammatory breast cancer patients

F. Clatot, F. Di Fioré, J. Lequesne, 2021, Scientific Reports.

Impact of Taxanes, Endocrine Therapy, and Deleterious Germline BRCA Mutations on Anti-müllerian Hormone Levels in Early Breast Cancer Patients Treated With Anthracycline- and Cyclophosphamide-Based Chemotherapy

F. Clatot, M. Lambertini, F. Di Fioré, 2019, Front. Oncol..

Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer

F. Clatot, M. Bubenheim, F. Di Fioré, 2020, Breast Cancer Research.

Molecular basis of agonist docking in a human GPR103 homology model by site‐directed mutagenesis and structure–activity relationship studies

H. Vaudry, J. Boutin, J. Chuquet, 2014, British journal of pharmacology.

Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor

F. Jardin, J. Picquenot, F. Clatot, 2016, Oncotarget.